News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
BioSpace News Archive
Browse BioSpace’s published news and press releases by year, month, and day.
269 Results
Year
2005 (24679)
2006 (34770)
2007 (39687)
2008 (39410)
2009 (42118)
2010 (39616)
2011 (38383)
2012 (38416)
2013 (36268)
2014 (39673)
2015 (44433)
2016 (38330)
2017 (37191)
2018 (39124)
2019 (51338)
2020 (57666)
2021 (58724)
2022 (53928)
2023 (42568)
2024 (38486)
2025 (17922)
Month
January (4345)
February (4356)
March (4476)
April (4722)
May (4999)
June (4103)
July (3643)
August (3330)
September (4039)
October (5056)
November (4470)
December (3799)
Day
1 (18)
2 (269)
3 (285)
4 (247)
5 (261)
6 (107)
7 (40)
8 (30)
9 (292)
10 (264)
11 (234)
12 (208)
13 (114)
14 (2)
15 (9)
16 (225)
17 (227)
18 (243)
19 (266)
20 (124)
21 (3)
22 (2)
23 (119)
24 (14)
25 (1)
26 (39)
27 (24)
28 (1)
29 (2)
30 (88)
31 (41)
Year
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Month
January
February
March
April
May
June
July
August
September
October
November
December
Day
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
Lilly to Participate in Evercore ISI 2nd Annual HealthCONx Conference
Eli Lilly and Company will participate in the Evercore ISI 2nd Annual HealthCONx Conference on Wednesday, December 4, 2019.
December 2, 2019
·
1 min read
Drug Development
1st Patient Dosed with Cellectis’ Allogeneic UCART22 in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Cellectis announced that the first patient enrolled in the dose escalation Phase 1 clinical study for its UCART22 product candidate has been dosed at The University of Texas MD Anderson Cancer Center.
December 2, 2019
·
5 min read
Pharm Country
Piper Jaffray to Host 31st Annual Healthcare Conference
Piper Jaffray Companies, a leading investment bank and institutional securities firm, will host its 31st annual Healthcare Conference in New York on December 3-5, 2019.
December 2, 2019
·
3 min read
FDA
US FDA 510(k) Clearance for Protein Calorie Malnutrition Assessment
The claims around PCM are to aid clinicians who are using Subjective Global Assessment (SGA) tools to assess patients at risk of PCM.
December 2, 2019
·
2 min read
Business
Signant Health Joins the Association of Clinical Research Organizations (ACRO) to Add a Technology Perspective to Conversations with Legislators and Industry Leaders about the Future of Clinical Research
As the 13th member company elected into ACRO, Signant Health bring its unique voice and views on patient-centricity and trial technology to the forefront
December 2, 2019
·
2 min read
Deals
Centene Corporation Announces Extension of Exchange Offers and Consent Solicitations for WellCare Notes
Centene Corporation announced the extension of the expiration date of the offers to exchange notes issued by WellCare Health Plans, Inc.
December 2, 2019
·
13 min read
Biotech Bay
Gastric Cancer Foundation 10th Anniversary Event Raises Over $250,000 To Support Gastric Cancer Programs And Research
Gastric Cancer Foundation Celebrates 10 Years Supporting the Gastric Cancer Community
December 2, 2019
·
3 min read
Policy
CMA pleased Premiers unite in making health care a priority in Canada
The Council of the Federation meeting in Toronto, Canada’s First Ministers placed our health care system where it belongs: at top of the agenda.
December 2, 2019
·
1 min read
Astellas Presents New Data on XOSPATA® (gilteritinib) in FLT3 Mutation-Positive Relapsed/Refractory Acute Myeloid Leukemia at the 2019 American Society of Hematology Annual Meeting
Emerging mutations in patients with treatment resistance, from Phase 3 ADMIRAL study, will be focus of oral presentation
December 2, 2019
·
13 min read
Drug Development
OSE Immunotherapeutics Announces Positive Results from Phase 1 Clinical Study of Anti-IL-7 Receptor Antagonist OSE-127
OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) today announced completion and positive results from the Phase 1 study of OSE-127, a humanized monoclonal antibody with a differentiated mechanism of action as a full-antagonist of the CD127 receptor, the alpha chain of the interleukin-7 receptor (IL-7R). OSE-127 has been shown in previous studies to induce a powerful antagonistic effect on effector T lymphocytes responsible for causing autoimmune diseases.
December 2, 2019
·
6 min read
Previous
10 of 27
Next